First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...

Among the many marvels of life is the cell's ability to divide and thus enable organisms to grow and renew themselves. For ...

– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a ...

For successful cell division, chromosomal DNA needs to be packed into compact rod-shaped structures. Defects in this process can lead to cell death or diseases like cancer. A new study has shown how ...

Engineered starfish oocytes shape-shift in response to light, may enable the design of synthetic, light-activated cells for ...

Scientists used light to control how a starfish egg cell jiggles and moves during its earliest stage of development. Their optical system could guide the design of synthetic, light-activated cells for ...

A hypoallergenic therapeutic vaccine candidate for peanut allergy was safe and tolerable, according to a poster presented at ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

Oncogene permanent activation in a single targeted cell of zebrafish together with a reprogramming factor transient activation is sufficient to induce the malignant transformation of the cell and ...

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...

Angle updates on AstraZeneca development work and Eisai’s phase 2 pilot study: London Tuesday, March 25, 2025, 11:00 Hrs [IST] Angle Inc, a world-leading liquid biopsy company w ...